Lunai Bioworks Inc. received a notification on April 28, 2026, from Nasdaq about potential delisting due to not meeting the $35 million market value requirement as of April 27, 2026. The company is attempting to comply with Nasdaq rules, including a planned reverse stock split approved on May 8, 2026, to regain compliance.